X-Ray structures of the LXRα LBD in its homodimeric form and implications for heterodimer signaling

Journal of Molecular Biology

Volumn 399, Issue 1, 2010, Pages 120-132

  Fradera, Xavier ^a   Vu, Diep ^a   Nimz, Olaf ^a   Skene, Robert ^b   Hosfield, David ^b   Wynands, Robert ^b   Cooke, Andrew J ^a   Haunsø, Anders ^a   King, Angela ^a   Bennett, D Jonathan ^a   McGuire, Ross ^a   Uitdehaag, Joost C M ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Takeda San Diego Inc   (United States)

Author keywords

Cholesterol; Crystal; GW3965; Helix 12; Interface

Indexed keywords

3 CHLORO 4 [3 (7 PROPYL 3 TRIFLUOROMETHYLBENZISOXAZOL 6 YLOXY)PROPYLTHIO]PHENYLACETIC ACID; 3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; BENZISOXAZOLE DERIVATIVE; BENZISOXAZOLE UREA; GW 9365; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; STEROID RECEPTOR COACTIVATOR 1; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CRYSTALLIZATION; DIMERIZATION; DRUG BINDING; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ANALYSIS;

EID: 77953083339     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2010.04.005     Document Type: Article

References (46)

1. Bensinger J.S., Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
2. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., et al. Synthetic LXR ligand inhibits the formation of atherosclerosis in mice. Proc. Natl Acad. Sci. USA 2002, 99:7604-7609.
3. Menke J.G., Macnaul K.L., Hayes N.S., Baffic J., Chao Y.S., Elbrecht A., et al. A novel liver X receptor agonist established species differences in the regulation of cholesterol 7α-hydroxylase (CYP7a). Endocrinology 2002, 143:2548-2558.
4. Shulman A.I., Mangelsdorf D.J. Retinoid X receptor heterodimers in the metabolic syndrome. N. Engl. J. Med. 2005, 353:604-615.
5. Bensinger J.S., Bradley M.N., Joseph S.B., Zelcer N., Janssen E.M., Hausner M.A., et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 2008, 134:97-111.
6. Greschik H., Moras D. Structure-activity relationship of nuclear receptor ligand interactions. Curr. Top. Med. Chem. 2003, 3:1573-1599.
7. Gronemeyer H., Gustafsson J.-Å., Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat. Rev., Drug Discov. 2004, 3:950-964.
8. Bennett D.J., Carswell E.J., Cooke A.J., Edwards A.S., Nimz O. Design, structure-activity relationships and X-ray cocrystallography of non-steroidal LXR agonists. Curr. Med. Chem. 2008, 15:195-209.
9. Williams S., Bledsoe R.K., Collins J.L., Boggs S., Lambert M.H., Miller A.B., et al. X-ray crystal structure of the liver X receptor β ligand binding domain. J. Biol. Chem. 2003, 278:27138-27143.
10. Gampe R.T., Montana V.G., Lambert M.H., Miller A.B., Bledsoe R.K., Milburn M.V., et al. Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 2000, 5:545-555.
11. Anderson L.M., Choe S.E., Yukhananov R.Y., Hopfner R.L., Church G.M., Pratt R.E., Dzau V.J. Identification of a novel set of genes regulated by a unique liver X receptor-α-mediated transcription mechanism. J. Biol. Chem. 2003, 278:15252-15260.
12. Lalloyer F., Pedersen T.Å., Gross B., Lestavel S., Yous S., Vallez E., et al. Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver. Arterioscler., Thromb., Vasc. Biol. 2009, 29:1488-1495.
13. Tamura K., Chen Y.E., Horiuchi M., Chen Q., Daviet L., Yang Z., et al. LXRα functions as a cAMP-responsive transcriptional regulator of gene expression. Proc. Natl Acad. Sci. USA 2000, 97:8513-8518.
14. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell 1995, 83:841-850.
15. Shulman A.I., Larson C., Mangelsdorf D.J., Ranganathan R. Structural determinants of allosteric ligand activation in RXR heterodimers. Cell 2004, 116:417-429.
16. Bourguet W., Vivat V., Wurtz J.M., Chambon P., Gronemeyer H., Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand binding domains. Mol. Cell 2000, 5:289-298.
17. Westin S., Kurokawa R., Nolte R.T., Wisely G.B., McInervey E.M., Rose D.W., et al. Interactions controlling the assembly of nuclear receptor heterodimers and co-activators. Nature 1998, 395:199-202.
18. Färnegårdh M., Bonn T., Sun S., Ljunggren J., Ahola H., Wilhelmsson A., et al. The three-dimensional structure of the liver X receptor β reveals a flexible ligand-binding pocket that can accommodate fundamentally different ligands. J. Biol. Chem. 2003, 278:38821-38828.
19. Hoerer S., Schmid A., Heckel A., Budzinski R.M., Nar H. Crystal structure of the human liver X receptor β ligand binding domain in complex with a synthetic agonist. J. Mol. Biol. 2003, 334:853-861.
20. Jaye M.C., Krawiec J.A., Campobasso N., Smallwood A., Qiu C., Lu Q., et al. Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure. J. Med. Chem. 2005, 48:5419-5422.
21. Washburn D.G., Hoang T.H., Campobasso N., Smallwood A., Parks D.J., Webb C.L., et al. Synthesis and SAR of potent LXR agonists containing an indole pharmacophore. Bioorg. Med. Chem. Lett. 2009, 19:1097-1100.
22. Svensson S., Ostberg T., Jacobsson M., Norstrom M., Stefansson K., Hallen D., et al. Crystal structure of the heterodimeric complex of LXRα and RXRβ ligand-binding domains in a fully agonistic conformation. EMBO J. 2003, 22:4625-4633.
23. Leslie A.G.W. Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMCB Newsletter on Protein Crystallography 1992, 26.
24. Pflughrath J.W. The finer things in X-ray diffraction data collection. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1999, 55:1718-1725.
25. Potterton E., Briggs P., Turkenburg M., Dodson E.J. A graphical user interface to the CCP4 program suite. Acta Crystallogr., Sect. D: Biol. Crystallogr. 2003, 59:1131-1137.
26. Murshudov G.N., Vagin A.A., Dodson E.J. Refinement of macromolecular structures by maximum-likelihood method. Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53:240-255.
27. Collins J.L., Fivush A.M., Watson M.A., Galardi C.M., Lewis M.C., Moore L.B., et al. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 2002, 45:1963-1966.
28. Lund E.G., Peterson L.B., Adams A.D., Lam M.N., Burton C.A., Chin J., et al. Different role of liver X receptor α and β in lipid metabolism: effects of an α-selective and a dual agonist in mice deficient in each subtype. Biochem. Pharmacol. 2006, 71:453-463.
29. Sierra M.L., Beneton V., Boullay A.B., Boyer T., Brewster A.G., Donche F., et al. Substituted 2-[(4-aminomethyl)-2-methylpropionic acid PPARα agonists. 1. Discovery of a novel series of potent HDLc raising agents. J. Med. Chem. 2007, 50:685-695.
30. Mi L.Z., Devarakonda S., Harp J.M., Han Q., Pellicciari R., Willson T.M., et al. Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol. Cell 2003, 4:1093-1100.
31. Watkins R.E., Davis-Searles P.R.D., Lambert M.H., Redinbo M.R. Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J. Mol. Biol. 2003, 331:815-828.
32. Egea P.F., Mitschler A., Rochel N., Ruff M., Chambon P., Moras D. Crystal structure of the human RXRα ligand binding domain bound to its natural ligand:9-cis-retinoic acid. EMBO J. 2000, 19:2592-2601.
33. McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science 2002, 296:1642-1644.
34. Willy P., Mangelsdorf D.J. Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR. Genes Dev. 1997, 11:289-298.
35. Van Durne J.J., Bettler E., Folkertsma S., Horn F., Vriend G. NRMD: nuclear receptor mutation database. Nucleic Acids Res. 2003, 31:331-333.
36. Albers M., Blume B., Schlueter T., Wright M.B., Kober I., Kremoser C., et al. A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors. J. Biol. Chem. 2006, 281:4920-4930.
37. The universal protein resource (UniProt). Nucleic Acids Res. 2008, 36:D190-D195. UniProt Consortium.
38. Gampe R.T., Montana V.G., Lambert M.H. Structural basis for autorepression of retinoid X receptor by tetramer formation and the AF-2 helix. Genes Dev. 2000, 14:2229-2241.
39. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. Nature 1998, 395:137-143.
40. Thompson P.D., Remus L.S., Hsieh J.-C., Jurutka P.W., Whitfield G.K., Galligan M.A., et al. Distinct retinoid X receptor activation function-2 residues mediate transactivation in homodimeric and vitamin D receptor heterodimeric contexts. J. Mol. Endocrinol. 2001, 27:211-227.
41. Egea P.F., Roche N., Birck C., Vachette P., Timmins P.A., Moras D. Effects of ligand binding on the association properties and conformation in solution of retinoic acid receptors RXR and RAR. J. Mol. Biol. 2001, 307:557-576.
42. Son Y., Park O.G., Kim G.S., Lee J.W., Lee Y.C. RXR heterodimerization allosterically activates LXR binding to the second NR box of activating signal co-integrator-2. Biochem. J. 2008, 410:319-330.
43. Costet P., Luo Y., Wang N., Tall A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 2000, 275:28240-28245.
44. Wiebel F.F., Steffensen K.R., Treuter E., Feltkamp D., Gustafsson J.-Å. Ligand independent coregulator recruitment by the triply activatable OR1/retinoid X receptor-α nuclear receptor heterodimer. Mol. Endocrinol. 1999, 13:1105-1118.
45. Ghosh J.C., Yang X., Zhang A., Lambert M.H., Li H., Xu E., Don Chen J. Interactions that determine the assembly of a retinoid X receptor/corepressor complex. Proc. Natl Acad. Sci. USA 2002, 99:5842-5847.
46. Chao E.Y., Caravella J.A., Watson M.A., Campobasso N., Ghisletti S., Billin A.N., et al. Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J. Med. Chem. 2008, 51:5758-5765.